Clinical trials: Lenvatinib Treatment
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05992584
- Testing
- Lenvatinib, sintilimab plus SIRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Biliary Tract Tumor
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
This study is a single-center, single-arm, open-label clinical study. All patients with advanced and unresectable biliary tract tumors will be treated with the combination of tisleizumab, lenvatinib and XELOX regimen (oxaliplatin…
- Trial name
- NCT05291052
- Testing
- Tislelizumab, Lenvatinib, Oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thyroid Carcinoma, Anaplastic
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.
- Trial name
- NCT02657369
- Testing
- Lenvatinib 24 mg
- Where
- 30 sites in United States, Australia and 3 more
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Mucosal Melanoma
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival.
- Trial name
- Neo PeLeMM (NCT05545969)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Australia
- Sponsor
- Melanoma Institute Australia
Hepatocellular Carcinoma Non-resectable
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
Currently in France, hepatocellular carcinoma (HCC) represents over 30% of indications of liver transplantation (LT) (# 500 cases/year).
- Trial name
- Ta-Len-Tra (NCT05901194)
- Testing
- Lenvatinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable…
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Trial name
- GDFATHERHCC01 (NCT07219459)
- Testing
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 104 people
- Sponsor
- CatalYm GmbH
Unresectable, Non-metastatic Hepatocellular Carcinoma
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma
- Trial name
- NCT05319431
- Testing
- AK104, Lenvatinib, TACE
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
HCC, Liver Cirrhosis
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically…
- Conditions
- HCC, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT07350070
- Testing
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Tongji Hospital
High Risk of Recurrence
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these…
- Trial name
- NCT06327269
- Testing
- Lenvatinib 10 mg
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Extensive-stage Small-cell Lung Cancer
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
- Trial name
- NCT05991180
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Hunan Province Tumor Hospital
Biliary Tract Neoplasms Immunotherapy
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
- Trial name
- NCT06362317
- Testing
- Toripalimab, Lenvatinib, Gemox Chemotherapy（Gemox or GC）
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Cancer
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
This study is an open label phase 2 study to evaluate the safety and efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the neoadjuvant / adjuvant treatment for Patients with Gastric Cancer.
- Trial name
- NCT04745988
- Testing
- Lenvatinib 20mg, Pembrolizumab, Lenvatinib 8mg
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- National Cancer Center Hospital East
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
This phase II study evaluates the efficacy and safety of Trastuzumab Rezetecan in combination with Adebrelimab and Lenvatinib as first-line therapy for patients with locally advanced or metastatic HER2-positive or HER2-low…
- Trial name
- NCT07670273
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation, Hepatocellular Carcinoma
Lenvatinib Therapy in HCC Patients After LDLT
New guidelines have been successfully established to distinguish the patients who were suitable for LT. This is important for long-term recurrence free and overall survival rate.
- Trial name
- NCT05572528
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaoshiung Chang Gung Memorial Hospital
Hepatoblastoma, Pediatric Cancer
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
This study is a single-cohort study. Pediatric patients with advanced, relapsed/refractory hepatoblastoma who have previously failed first-line or higher systemic therapy will receive 2 cycles of treatment with sintilimab…
- Trial name
- NCT07188311
- Testing
- Pucotenlimab ,Lenvatinib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Kaposi Sarcoma, Classic Kaposi Sarcoma
Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
Phase II study of Pembrolizumab plus Lenvatinib in relapsed/refractory Classic Kaposi Sarcoma (CKS). After a screening phase of up to 28 days, each participant will receive study intervention of pembrolizumab plus lenvatinib…
- Conditions
- Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma
- Trial name
- PULSAR (NCT05846724)
- Testing
- Pembrolizumab + Lenvatinib
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cholangiocarcinoma, Intrahepatic
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and immune checkpoint inhibitor PD-1 antibody (JS001) for patients…
- Trial name
- NCT03951597
- Testing
- combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital